SEARCH:   Advanced

Blood, 25 June 2009, Vol. 113, No. 26, pp. 6572-6575. Prepublished online as a Blood First Edition Paper on April 23, 2009; DOI 10.1182/blood-2009-02-207803. This Article Full Text (PDF) All Versions of this Article: blood-2009-02-207803v1 113/26/6572    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Nair, B. Articles by Barlogie, B. Search for Related Content PubMed PubMed Citation Articles by Nair, B. Articles by Barlogie, B. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 26, 2009 Accepted April 6, 2009 Gene expression profiling of plasma cells at myeloma relapse from total therapy 2 predicts subsequent survival Bijay Nair, John D. Shaughnessy Jr, Yiming Zhou, Marie Astrid-Cartron, Pingping Qu, Frits van Rhee, Elias Anaissie, Yazan Alsayed, Sarah Waheed, Klaus Hollmig, Jackie Szymonifka, Nathan Petty, Antje Hoering, and Bart Barlogie* Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, United States Cancer Research and Biostatistics, Seattle, WA, United States * Corresponding author; email: barlogiebart{at}uams.edu. We report on prognostic implications for post-relapse survival (PRS) of a gene expression profiling (GEP)-defined risk score at relapse available in 120 myeloma patients previously enrolled in Total Therapy 2. Among the 71 patients with additional GEP baseline information, 3-yr PRS was 71% in 40 patients with low-risk present both at baseline and relapse contrasting with only 17% in 28 patients with relapse high-risk, 12 of whom with baseline low-risk status fared better than the remainder (p=0.08). On multivariate analysis of relapse parameters available in 104 patients, high-risk conferred short PRS (HR=4.00, p<0.001, R2=33%) while relapse Hyperdiploidy predicted long PRS (HR=0.37, p=0.022, cumulative R2=41%). In case the initial partial response lasted less than 2 years, relapse low-risk identified 26 patients with superior 3-yr PRS of 61% v 9% among 32 with relapse high-risk (p<0.001). Based on its PRS predictive power, GEP analysis should be an integral part of new agent trials in search of better therapy for high-risk myeloma. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020